Michael J. Fox Foundation and Parkinson’s UK Award $5.2 Million to Mission Therapeutics for Research into Potential Parkinson’s Treatment

Posted on by admin
1 min read

MTX325 is in Phase I trials and is believed to be able to modify the course of the disease.

Avatar for admin
admin https://goorre.com

You May Also Like

More From Author

+ There are no comments

Add yours